DNASE1 and embryonal carcinoma: Therefore, we designed the preclinical study to evaluate the effect of DNase I treatment alone and in combination with CDDP on the xenografts derived from the human embryonal carcinoma (EC) chemoresistant cell line variant NT2 CisR.